Mining the Aging Transcriptome Turns Up Seven New Life-Extending Compounds (in Worms)

A Singapore team argues that a popular way of hunting for anti-aging drugs, finding compounds that reverse age-related gene expression, is flawed because some of those changes are protective. They broke the ageing worm transcriptome into clusters of co-regulated genes, identified clusters tied to lifespan across 25 published datasets, and used five of them to search a human drug-response database. Of 15 compounds picked, 10 extended lifespan in C. elegans, seven of them previously unreported. Some gene clusters were also found in ageing mouse muscle and tracked with frailty. The new compounds have been tested only in worms.

Many attempts to find drugs that slow ageing rest on a simple rule: work out which genes change their activity with age, then look for compounds that push them back. Brian Kennedy, Jan Gruber and colleagues at the National University of Singapore report that this rule breaks down in practice, and they propose a replacement that produced a run of hits in worms.

The group first built a “transcriptomic clock” for the nematode C. elegans, a model that estimates biological age from gene activity. It worked on untreated worms and correctly rated a long-lived mutant as younger. When applied to worms given known life-extending drugs, it rated most of them as older than their true age. Only rapamycin made worms look younger. Long-lived worms with reduced insulin signalling also read as old.

The explanation the authors offer is that ageing animals switch on defensive programmes, and life-extending drugs switch on the same programmes early. A clock cannot distinguish damage from defence. Published mouse liver data showed the same thing: at six months, treatments such as rapamycin produced an “older” gene profile, which faded or reversed by twelve months.

To separate the two, the team grouped worm genes into 62 clusters, or modules, that rise and fall together. They compared how each module behaved in ageing and in worms lacking daf-16, a master stress-response gene. Modules that moved in opposite directions were treated as candidate protective responses. A meta-analysis of 25 public datasets then showed which modules tracked lifespan. Lower activity of mitochondrial and ribosomal modules went with longer life, as did higher activity of stress-defence modules.

Five of these modules were converted to their human gene equivalents and used to query the Connectivity Map, a catalogue of how human cell lines respond to thousands of compounds. From 223 matches the team chose 15 to test. Eleven lengthened worm lifespan in a first screen and ten held up in a stricter repeat. The team sequenced RNA from worms given the two best performers, the cough medicine ingredient bromhexine and the plant compound genipin, and both shifted the modules roughly as predicted.

Several worm modules also appeared in ageing mouse soleus muscle. One mitochondrial and ribosomal module rose with frailty in old male mice. Dietary alpha-ketoglutarate, a compound Kennedy has studied before, suppressed it.

There are several reasons for caution. The comparison behind the headline hit rate is not like for like, and no randomly chosen drugs were run through the same assay. Five of the 15 candidates were already known to extend worm lifespan. Bromhexine made the worms smaller and delayed their reproduction, a pattern that often signals reduced feeding. None of the new compounds has been tested for lifespan in a mammal.

Actionable Insights

Nothing in this study supports taking any of the newly identified compounds for longevity. The evidence is from worms only.

  1. Size of the effect. In worms, the best compounds raised median lifespan by roughly 20 to 37 percent in the first screen. In the stricter repeat the authors report gains of up to 4 days. Control worms in those experiments lived about three weeks, so that is closer to 20 percent by my reading of the survival curves.
  2. Worm results translate poorly. Hundreds of compounds extend worm lifespan and very few have done so in mice. Treat these as leads for researchers.
  3. Several hits are prescription drugs with real risks (clopidogrel, prednisolone, riluzole, atenolol, indapamide). Riluzole shortened worm life at the highest dose.
  4. Be sceptical of “biological age” readouts after starting an intervention. In this work, effective treatments made gene-expression clocks read older in the short term. This was shown for transcriptomic clocks in worms and mouse liver. It has not been shown for human epigenetic clocks.
  5. Alpha-ketoglutarate improved frailty scores in old male mice only at the 4 percent dietary dose. Scaled by body surface area, 2 percent of diet corresponds to something like 15 to 20 grams a day for an adult human by my estimate, far above typical supplement doses. [Confidence: Low]

Context/Source

  • Open Access Paper: Predicting and finding geroprotective compounds through modulating conserved longevity-associated aging modules,
    30 Sep 2026.
  • Authors: Weihan Huai and Li-Fang Ng (joint first), with Brian K. Kennedy and Jan Gruber as corresponding authors
  • Institution: Yong Loo Lin School of Medicine, National University of Singapore; Centre for Healthy Longevity, National University Health System; Yale-NUS College
  • Country: Singapore
  • Journal: Science Advances, 2026; 12:eaee3657 (published 30 September 2026)
  • Competing interests: Kennedy is scientific advisor and board member of PDL Health. To my knowledge that company (Ponce De Leon Health) markets a calcium alpha-ketoglutarate supplement, which is the compound used in the mouse experiments here. [Confidence: Medium]
  • Impact evaluation: The impact score of this journal is 13.9, evaluated against a typical high-end range of 0–60+ for top general science, therefore this is a High impact journal.
1 Like

Yes, this has been my longstanding critique of anti-aging interventions. We don’t know which age-related changes are protective and adaptive and which are age-related deterioration. Correcting the deterioration is the goal, reversing the protection and adaptation is counterproductive. We see this over and over again. I think that’s the major flaw in Mike Lustgarten’s approach - trying to get all biomarkers to youthful levels - you don’t know what is actually protective/adaptive age-related change, best left alone.

I’m glad someone is looking at this question. Whether this is the optimal approach remains to be seen, but it’s a start.

2 Likes

chatGPT(6AstraMaxPaid):

what compounds did they try and what were the lifespan results?

They screened 15 candidate compounds plus four positive controls in C. elegans. I located Supplementary Table S6, which provides the exact results.

Below, percentages are changes in median lifespan relative to the corresponding control, rounded to one decimal. The first three columns are the initial screen. Validation used different conditions, without FUDR or carbenicillin.

Positive screening percentages were not always statistically significant. In the validation column, increases are statistically significant unless stated otherwise. Concentrations are in micromolar, abbreviated uM.

Candidate compound Screen: 2 uM Screen: 20 uM Screen: 200 uM Subsequent validation
Bromhexine +15.8% +15.8% +36.8% +22.2% at 200 uM
Genipin +22.7% +27.3% +31.8% +17.6% and +22.2% in two experiments at 200 uM
Eudesmic acid +13.6% +18.2% +22.7% +11.1% at 200 uM
Galantamine +13.6% +22.7% +22.7% +5.6% at 200 uM
Kavain +16.7% +25.0% -12.5% +22.2% at 20 uM
Taxifolin +3.8% +7.7% +23.1% +22.2% at 200 uM
Piperlongumine +16.7% +12.5% +4.2% +11.1% at 2 uM
Prednisolone +12.5% +12.5% 0% +23.5% at 20 uM
Indapamide 0% +12.5% +12.5% +11.8% at 200 uM
Riluzole +8.0% +8.0% -36.0% +11.8% at 20 uM
Clopidogrel +4.0% +4.0% -12.0% +5.9% at 20 uM
Ezetimibe +8.0% 0% -4.0% 0%, no significant benefit at 2 uM
Sulconazole +3.8% -11.5% Not reported in Table S6 +5.6% at 2 uM, not significant
Atenolol 0% 0% 0% 0%, no significant benefit at 200 uM
Nortriptyline 0% 0% 0% -5.9% at 100 uM, significant shortening

Bromhexine was additionally tested at 0.2 uM, producing a significant 15.8% increase in the initial screen.

The four positive controls gave these initial-screen results:

Positive control 2 uM 20 uM 200 uM
Rapamycin +12.0% +12.0% +12.0%
Urolithin A +12.0% +12.0% +8.0%
Curcumin +8.0% +12.0% -8.0%
Aspirin +4.0% +4.0% 0%

Rapamycin’s increases were significant at all three concentrations. Urolithin A was significant at 2 and 20 uM, but not 200 uM. Curcumin significantly extended lifespan at 20 uM and shortened it at 200 uM. Aspirin did not meet the study’s screening criterion for lifespan extension.

Several details matter when interpreting these results:

  • The largest initial-screen result was bromhexine’s 36.8%. Its listed validation result was 22.2%.
  • Prednisolone produced the largest percentage increase in the listed validation experiments: 23.5%. The compounds were tested against different control cohorts, so this is not a definitive ranking.
  • Dose could reverse the effect. Riluzole, kavain and clopidogrel shortened lifespan at 200 uM despite benefits at lower concentrations.
  • Atenolol showed no lifespan benefit in either stage.
  • The headline count needs qualification. The paper reports 10 validated hits. Table S6 also lists a significant positive validation result for clopidogrel, giving 11 positive compounds in that table. Clopidogrel’s initial increase was below the screening cutoff of greater than 5%, which appears to explain its exclusion from the headline count.

In mice, they tested 2% and 4% dietary calcium alpha-ketoglutarate. Those experiments assessed frailty and gene expression; they did not report a mouse lifespan-extension result.

Source: Supplementary Table S6, within the article’s supplementary files.

1 Like

source: this post

My view on C. Elegans is that it is not a particularly good model. My view is that it has a particularly short lifespan because it has no BER enzymes in the mitochondria. In particular OGG1 is missing as is an equivalent to MUTYH (MTH1)

However, I have prompted Claude on the interventions that go for over 10%. (I exhausted my chatGPT budget on the previous questions) Opus5.5 medium.

Noting the uploaded paper and supplementary tables what are the modes of action of the following list of interventions and are there any other lifespan experiments and what were the outcomes of those Bromhexine Genipin Eudesmic acid Galantamine Kavain Taxifolin Piperlongumine Prednisolone Indapamide

What the paper itself found

All nine are CMap-predicted hits validated in C. elegans N2. From Table S6, screening (FUDR/carbenicillin) then validation (cold-inactivated bacteria, no FUDR):

Compound Best screen dose / median extension Validation result
Bromhexine 200 ”M, +36.8% +22.2% median (p<0.0001)
Genipin 200 ”M, +31.8% +22.2% and +17.6% in two runs
Eudesmic acid 200 ”M, +22.7% +11.1% (p=2×10⁻⁎)
Galantamine 20–200 ”M, +22.7% +5.6% (p=0.017)
Kavain 20 ”M, +25% +22.2% (p=1×10⁻⁶)
Taxifolin 200 ”M, +23.1% +22.2% (p<0.0001)
Piperlongumine 2 ”M, +16.7% +11.1% (p=2.6×10⁻⁎)
Prednisolone 2–20 ”M, +12.5% +23.5% median / +12.4% mean (p=2.7×10⁻⁎)
Indapamide 200 ”M, +12.5% +11.8% (p=0.001)

Note the dose inversions: piperlongumine and kavain are best at low ”M and lose or reverse benefit at 200 ”M (kavain at 200 ”M was −12.5%), consistent with hormesis. Prednisolone and indapamide validated better than they screened.

Of these, five were flagged in the paper as having prior C. elegans evidence (galantamine, piperlongumine, taxifolin, plus ezetimibe and nortriptyline); bromhexine, genipin, eudesmic acid, kavain, prednisolone and indapamide were the novel set.

Modes of action

Bromhexine — mucolytic (Boehringer, benzylamine derived from vasicine); parent of ambroxol. Clinically it reduces mucus viscosity and is a weak Nav1.8 blocker; it’s also a TMPRSS2 inhibitor (hence COVID interest). Geroprotective relevance: the ambroxol/bromhexine axis is linked to glucocerebrosidase chaperoning, TFEB activation and macroautophagy induction. In this paper, bromhexine upregulated metabolic and proteasome pathways (enhanced proteostasis) but, unexpectedly, also activated aging modules M2.1–M2.3 and M3.4 — a signature it shares with rapamycin (r=0.45 genome-wide, 629 co-upregulated genes). Both also extended reproductive span and reduced body size, suggesting a growth/germline-signalling component.

Genipin — aglycone of geniposide from Gardenia jasminoides; a UCP2 inhibitor, protein crosslinker, and Nrf2/SKN-1 activator with anti-inflammatory (NF-ÎșB) activity. Here it was the cleanest hit mechanistically: it positively regulated all five longevity modules used as CMap input, with upregulation of oxidoreductase and myofibril genes, and only 199 DEGs — a narrow, targeted signature versus bromhexine’s 5,141.

Eudesmic acid (3,4,5-trimethoxybenzoic acid, trimethylgallic acid) — O-methylated gallic acid from Eucalyptus; also the active metabolite of trimebutine. Antioxidant, cytokine-production inhibitor, weak antibacterial. Mechanism in aging is essentially unexplored; the methylation improves lipophilicity and metabolic stability over gallic acid.

Galantamine — reversible acetylcholinesterase inhibitor and allosteric potentiator of nicotinic ACh receptors; licensed for Alzheimer’s. The nicotinic/cholinergic anti-inflammatory pathway and autophagy/mitophagy effects are the plausible geroprotective routes.

Kavain — kavalactone from Piper methysticum; GABA_A positive modulator, voltage-gated Naâș/CaÂČâș channel blocker, inhibitor of TNF-α via ERK/LITAF and of NFATc1. In worms it enhances cholinergic transmission at the NMJ and inhibits advanced glycation end-product formation.

Taxifolin (dihydroquercetin) — flavanonol; ROS scavenger, Nrf2/SKN-1 inducer, inhibits fibril formation and advanced glycation, modest AMPK effects.

Piperlongumine — amide alkaloid from Piper longum; a thiol-reactive electrophile that raises ROS selectively in stressed cells, inhibits GSTP1 and TrxR1, has HDAC-inhibitory activity, and is a first-generation senolytic acting partly via OXR1 and PI3K/Akt/mTOR inhibition.

Prednisolone — synthetic glucocorticoid receptor agonist; transrepresses NF-ÎșB and AP-1. Worms have no canonical GR, so the worm effect is almost certainly off-target (nuclear hormone receptor family NHR-8/DAF-12 or stress-response crosstalk) rather than classical glucocorticoid signalling. Worth flagging given chronic glucocorticoids cause sarcopenia, insulin resistance and bone loss in mammals.

Indapamide — thiazide-like sulphonamide diuretic; inhibits the Naâș/Cl⁻ symporter in the distal tubule, with additional calcium-channel and antioxidant/vasodilatory actions. Again no obvious worm target; the module-level effect may run through osmotic/ion-homeostasis stress responses, which is notable because M1.1 (the top longevity module) is enriched for ion transport and plasma membrane genes.

Other lifespan experiments in the literature

Bromhexine/ambroxol. No independent published worm or fly lifespan study I can find. The relevant data is in patent WO2019018247A1 (Neuere LLC): male BDF1 mice fed ambroxol at 50 mg/kg/day from 2 months of age showed increased lifespan versus controls, with a parallel dose-dependent improvement in novel place recognition at 7 months, and ambroxol induced macroautophagy in NIH3T3 cells. Caveats: patent data, group sizes 22–25, experiment terminated at 16 months, no peer review. Ambroxol is in Phase 2/3 human trials for Parkinson’s and GBA-PD, so human safety data exists.

Genipin. Strong supporting literature via geniposide. A geniposide-rich Gardenia jasminoides fruit extract increased C. elegans lifespan by 27.1%, and 10 mM geniposide alone increased lifespan by 18.55%, with improved pharyngeal pumping, muscle quality, reduced age pigment and ROS, and protection against AÎČ1-42 toxicity; the effects were attributed to inhibition of insulin/IGF-1 signalling and activation of SKN-1/Nrf. Geniposide also restored lifespan and motility in an AÎČ C. elegans model and ameliorated physical function decline in SAMP8 mice, inhibiting FoxO1 via AKT activation. So genipin now has convergent evidence across two independent labs and a mammalian healthspan dataset.

Galantamine. Tezze et al. (2023, JCI Insight) found galantamine alone gave +6.8% mean lifespan in C. elegans — less than metformin — while the combination RJx-01 (metformin + galantamine) gave +22.1%, significantly greater than either component, with improved movement. That was 25 mM metformin + 100 ”M galantamine over 29 days, working through autophagy/lysosomal and mitochondrial-quality pathways. The Huai validation (+5.6%) replicates the small galantamine-alone effect almost exactly. RJx-01 has since gone into human sarcopenia trials.

Kavain. Upadhyay et al. (2014) reported kavain increases C. elegans lifespan at 40 and 80 ”M by inhibiting advanced glycation end-products, and kavain at 50 ”M suppressed AÎČ-induced paralysis in the GMC101 strain. Separately, 1 mg/mL kavain induces paralysis in wild-type worms via disrupted cholinergic transmission — which fits the toxicity Huai et al. saw at 200 ”M. Kava hepatotoxicity is the obvious translational barrier.

Taxifolin. Benedetti et al. (2008, Exp Gerontol) identified it in a screen for compounds conferring thermal stress resistance and extended lifespan — the reference the authors cite. In mice, a triple combination of quercetin, taxifolin and pycnogenol did not increase lifespan (Spindler et al.). A very recent paper reports a taxifolin-zinc nanozyme with SOD-like activity that extended lifespan and improved healthspan indicators in C. elegans, though that’s a formulation effect as much as a taxifolin effect.

Piperlongumine. Grigolon et al. (2022, Nat Commun) found piperlongumine extended nematode lifespan by >10% in a GRH-1-dependent manner, alongside vorinostat (+12.3%) and papaverine (+11.4%); piperlongumine is also an HDAC inhibitor. In the BXD mouse reference population, Grhl1 expression correlates positively with lifespan and insulin sensitivity, and in humans GRHL1 expression correlates with insulin receptor signalling and lifespan. Separately it was identified as one of the first senolytics alongside ABT-263, from a screen in irradiation-induced senescent WI-38 fibroblasts — but I’m not aware of any published mouse lifespan trial for piperlongumine itself.

Prednisolone. No lifespan-extension literature. The nearest relevant data runs the other way: in a mouse carcinogenicity bioassay, high-dose prednisone reduced 18-month survival to 44% (males) and 52% (females) versus 74–94% at ≀1.0 mg/kg/day, largely through infection-related deaths, though it did not increase spontaneous cancer risk. In worms, dexamethasone is routinely used as a positive control for inducing muscle atrophy. This is the hit I’d treat most sceptically.

Indapamide. No model-organism lifespan work. But it has the best human mortality evidence of the nine: HYVET randomised 3,845 hypertensive patients aged over 80 to indapamide SR 1.5 mg (± perindopril) or placebo and was stopped early, showing a 21% reduction in total mortality (HR 0.79, 95% CI 0.65–0.95), 39% reduction in fatal stroke, and 64% reduction in heart failure. A one-year open-label extension showed continued all-cause and cardiovascular mortality benefit, and secondary analyses suggested possible protection against incident fractures and dementia. That’s disease-mechanism mortality reduction rather than rate-of-ageing modification, and a later meta-analysis found no overall total-mortality effect in this population (RR 0.97, 95% CI 0.87–1.08) despite a clear stroke reduction — so the HYVET result is contested.

Eudesmic acid. Nothing. No lifespan data in any organism that I can find, and essentially no aging literature. The one oddity worth noting: 3,4,5-trimethoxybenzoic acid has documented nematicidal activity against Heterodera zeae at 0.125–1%, so at high concentration in worms you are near a toxic compound — which is exactly the hormetic territory the authors warn about (“stress-inducing compounds can also perturb these modules”).

Where I’d put the weight

Genipin is the strongest candidate: independent replication, a mammalian healthspan dataset, a coherent IIS/SKN-1 mechanism, and the cleanest module signature in this paper. Galantamine has the most translational momentum. Indapamide and prednisolone are the two where the worm result and the mammalian pharmacology point in opposite directions, and eudesmic acid is the genuine unknown — which, from a discovery standpoint, is also the most interesting thing in the list.

One structural caveat across all of these: the first-round screen used FUDR and live carbenicillin-treated bacteria, and several compounds here (eudesmic acid, bromhexine, piperlongumine) have direct antibacterial activity. The validation round with cold-inactivated bacteria mitigates this, but doesn’t fully exclude a diet-mediated component.

1 Like